• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
We examined the association between glucose-lowering medications and a broad range of cardiovascular outcomes, and assessed the strength of evidence for these associations.MethodsFor this umbrella review we searched PubMed, Embase, and the Cochrane Library to identify systematic reviews and meta-analyses of randomised controlled trials examining the cardiovascular safety of glucose-lowering medications. Cardiovascular outcomes examined included major adverse cardiovascular events, cardiovascular death, myocardial infarction, stroke, heart failure, unstable angina, and atrial fibrillation. For each meta-analysis, we estimat...
Source: The Lancet Diabetes and Endocrinology - January 30, 2020 Category: Endocrinology Source Type: research

Incidence of adverse cardiovascular events in type  2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
ConclusionsThe incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial.
Source: Journal of Diabetes Investigation - January 29, 2021 Category: Endocrinology Authors: Shun Kohsaka, Hiraku Kumamaru, Shiori Nishimura, Satoshi Shoji, Eiji Nakatani, Nao Ichihara, Hiroyuki Yamamoto, Yoshiki Miyachi, Hiroaki Miyata Tags: Original Article Source Type: research

Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
ConclusionsAvailable data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
Source: Acta Diabetologica - August 3, 2016 Category: Endocrinology Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Modeling Effects of SGLT‐2 Inhibitor Dapagliflozin Treatment vs. Standard Diabetes Therapy on Cardiovascular and Microvascular Outcomes
ConclusionsBased on these simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - January 20, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H.L. Grossman, M. Cohen Tags: Original Paper Source Type: research

Modeling Effects of SGLT-2 Inhibitor Dapagliflozin Treatment vs. Standard Diabetes Therapy on Cardiovascular and Microvascular Outcomes.
CONCLUSIONS: Based on these simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM. PMID: 24443793 [PubMed - as supplied by publisher]
Source: Diabetes Metab - January 20, 2014 Category: Endocrinology Authors: Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E, Perlstein I, Grossman HL, Cohen M Tags: Diabetes Obes Metab Source Type: research

Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
ConclusionsOn the basis of simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - February 19, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H. L. Grossman, M. Cohen Tags: ORIGINAL ARTICLE Source Type: research

Benefits of SGLT2 Inhibitors beyond glycemic control - A focus on metabolic, cardiovascular, and renal outcomes.
CONCLUSIONS: SGLT2 inhibitors demonstrate some positive metabolic effects. In addition, empagliflozin specifically has demonstrated reduction in cardiovascular events and delay in the progression of kidney disease in patients with T2DM and a history of cardiovascular disease. Further data is needed to assess if this is a class effect. PMID: 28814245 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - August 16, 2017 Category: Endocrinology Authors: Minze MG, Will K, Terrell BT, Black RL, Irons BK Tags: Curr Diabetes Rev Source Type: research

Can we go beyond surrogates?
Two years ago, data presented at the annual American Diabetes Association (ADA) meeting in New Orleans showed a marked decrease in deaths, especially those due to cardiovascular disease, with the use of empagliflozin. Two major questions have been asked: (i) was the result a fluke; and (ii) was it a class effect, or was it specific to the agent used? The hope that both questions would be answered by a second study has been answered: the conclusions of EMPA‐REG were not an anomaly and it is a class effect, not one caused by a specific drug. Importantly, do these studies require us to alter our algorithms for the treatment...
Source: Journal of Diabetes - October 19, 2017 Category: Endocrinology Authors: Andrew Drexler Tags: Editorial Source Type: research

A Multinational Real-World Study on the Clinical Characteristics of Patients with Type  2 Diabetes Initiating Dapagliflozin in Southern Europe
ConclusionsSignificant differences were seen among patients initiating dapagliflozin in southern Europe. Our results suggest that dapagliflozin was being initiated at different stages of the disease according to the country and prescribing settings. Such geographic heterogeneity may have an impact upon effectiveness of dapagliflozin on glucose lowering, as well as cardiovascular and renal outcomes.
Source: Diabetes Therapy - December 19, 2019 Category: Endocrinology Source Type: research